Exposure–Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies

2017 ◽  
Vol 37 (7) ◽  
pp. 647-657 ◽  
Author(s):  
Chih-Wei Lin ◽  
Rajeev Menon ◽  
Wei Liu ◽  
Thomas Podsadecki ◽  
Nancy Shulman ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Phase Iii ◽  
Response Relationship ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Chronic Hepatitis C Virus ◽  
Phase Iii Studies

scholarly journals Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

Hepatology ◽  
2015 ◽  
Vol 62 (1) ◽  
pp. 25-30 ◽  
Author(s):  
Saleh A. Alqahtani ◽  
Nezam Afdhal ◽  
Stefan Zeuzem ◽  
Stuart C. Gordon ◽  
Alessandra Mangia ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Phase Iii ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Chronic Hepatitis C Virus

Deferred treatment with a fixed‐dose combination of sofosbuvir‐velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection

2019 ◽  
Vol 26 (10) ◽  
pp. 1229-1232
Author(s):  
Tarik Asselah ◽  
Stephen D. Shafran ◽  
Stefan Bourgeois ◽  
Ching‐Lung Lai ◽  
Philippe Mathurin ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Fixed Dose ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Deferred Treatment ◽  
Chronic Hepatitis C Virus ◽  
Dose Combination
Sign in / Sign up

Export Citation Format

Share Document